Amarin Corporation plc

Contributing Author

Recent Articles by Amarin Corporation plc

Aug-31	Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 AMRN GlobeNewswire
Aug-30	New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups AMRN GlobeNewswire
Aug-25	New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 AMRN GlobeNewswire
Jul-30	Amarin Reports Second Quarter 2025 Financial Results AMRN GlobeNewswire
Jul-23	Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025 AMRN GlobeNewswire
Jun-24	Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA (Icosapent Ethyl) in Europe AMRN GlobeNewswire
May-07	Amarin Reports First Quarter 2025 Financial Results AMRN GlobeNewswire